Amicus slips after Plicera data

Amicus Therapeutics Inc. (NASDAQ:FOLD) fell $2.94 (35%) to $5.56 on Monday after announcing late Friday that it does not expect to progress Plicera afegostat into Phase III trials at this time. Plicer...